Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prostate Cancer Stereotactic Radiotherapy (ESKO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02319239
Recruitment Status : Recruiting
First Posted : December 18, 2014
Last Update Posted : March 28, 2019
Sponsor:
Information provided by (Responsible Party):
Tampere University Hospital

Brief Summary:

Primary purpose of the study is to develop a stereotactic radiation treatment to prostate cancer which minimizes treatment related toxicity. Movement of the prostate during a radiation therapy will be monitored by temporary implanted electromagnetic transmitter. This data will be used to define prostate marginals (PTV) for stereotactic treatment. Radiation toxicity to rectum will be reduced by using a rectum fixation during a treatment.

Study group I (20 patients) will be treated 39 x 2 Gy and study group II (20 patients) with 20 x 3 Gy fractionation schedules. With the data collected from these groups treatment marginals to prostate will be defined and used to treat group III (40 patients) with 5 x 7.25 Gy.

Second purpose of this study is to assess if Diffusion-weighted magnetic resonance imaging could be used to evaluate radiation treatment response in intermediate prostate cancer. Androgen deprivation therapy is not allowed in this study.


Condition or disease Intervention/treatment Phase
Prostate Neoplasms Toxicity Due to Radiotherapy Radiation: Fractionation Radiation: hypofractionation Radiation: stereotactic fractionation Not Applicable

Detailed Description:

New local prostate cancer patients needing external radiotherapy are included into three radiation dose groups;

Group I will be treated normal dosing (39 x 2 Gy) and study group II with hypofractionated dosing (20 x 3 Gy) and group III extreme hypofractionationated dosing. Primary goal is to develop safe and effective curative radiotherapy for these patients

Second aim is to study Diffusion-weighted magnetic resonance image in radiation treatment response in intermediate prostate cancer.

Patients are followed by MRI, PSA, bone scans and quality of life questionaries.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Development of Prostate Cancer Stereotactic Radiotherapy in Tampere Using Intra-fractional Movement Detector and Diffusion-weighted Magnetic Resonance Imaging.
Study Start Date : May 2014
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Active Comparator: Conventional fractionation
During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
Radiation: Fractionation
During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.

Experimental: hypofractionation
During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.
Radiation: hypofractionation
During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months

Experimental: Stereotactic fractionation
During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.
Radiation: stereotactic fractionation
During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months




Primary Outcome Measures :
  1. To determine whether the temporary implanted electromagnetic transmitter could be used to reduce treatment marginals in prostate cancer radiation therapy [ Time Frame: 1 to 3 months ]
    PSA recurrence


Secondary Outcome Measures :
  1. Evaluation of DW-MRI to predict the outcome of prostate cancer radiation therapy [ Time Frame: 0 - 12 months ]
    PSA recurrence

  2. quality of life [ Time Frame: 1 to 3 months ]
    quality of life questionaires



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biopsy-proven prostate Cancer
  • One or two risk factors for intermediate prostate cancer:

    • Gleason score 7
    • T2b-T2c
    • PSA 10-20 microg/l
  • No need for androgen deprivation therapy
  • Eligible fo MRI
  • Radical radiotherapy

Exclusion Criteria:

  • Locally advanced or metastatic prostate cancer
  • Previous RT to pelvic reason
  • Other severe disease
  • Previous cancer within 5 years
  • Severe urinary symptoms at the start of the study (I-PSS over 20)
  • Wide cavity after TURP

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02319239


Contacts
Layout table for location contacts
Contact: Pirkko-Liisa Kellokumpu-Lehtinen, MD,PhD +358331163227 pirkko-liisa.kellokumpu-lehtinen@pshp.fi

Locations
Layout table for location information
Finland
Tampere University Hospital Recruiting
Tampere, Finland, 33521
Contact: Pirkko-Liisa Kellokumpu-Lehtinen       klpike@uta.fi   
Sub-Investigator: Petri Reinikainen, MD         
Sponsors and Collaborators
Tampere University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Petri Reinikainen Tampere Unviersity Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Tampere University Hospital
ClinicalTrials.gov Identifier: NCT02319239    
Other Study ID Numbers: ETL R14009
R14009 ( Other Identifier: TampereUH )
First Posted: December 18, 2014    Key Record Dates
Last Update Posted: March 28, 2019
Last Verified: March 2019
Keywords provided by Tampere University Hospital:
Prostate neoplasms
Urogenital neoplasms
Genital neoplasms, male
Radiation therapy
PSA
DW-MRI, diffusion weighted MRI
Intra-fractional movement
Hypofractionated radiotherapy
Stereotactic
Toxicity due to radiotherapy
Quality of life
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases